BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
Rhea-AI Summary
BioNTech (Nasdaq: BNTX) will report fourth quarter and full year 2025 financial results on March 10, 2026. A live conference call and webcast for investors and analysts is scheduled for 8:00 a.m. ET (1:00 p.m. CET) that day.
Slides and audio will be available on the company website, with a replay archived for 30 days.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Among close biotech peers, scanner activity only flagged GMAB, down 0.85%, while BNTX was down 0.2%. With just one peer in momentum and mixed moves across others, today’s setup appears stock-specific rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 28 | Management appointment | Positive | -2.7% | New Chief People Officer added to Management Board for people strategy. |
| Jan 12 | Strategic update | Positive | +2.3% | Outlined 2026 focus with strong cash and oncology pipeline plans. |
| Dec 18 | Acquisition close | Positive | -0.1% | Closed CureVac acquisition to strengthen mRNA capabilities and oncology strategy. |
| Dec 09 | Clinical data update | Positive | -1.5% | Phase 2 pumitamig data showed encouraging efficacy in TNBC. |
| Dec 03 | Exchange offer milestone | Positive | +0.7% | Achieved minimum condition in CureVac exchange offer with high tender rate. |
Recent positive strategic and clinical news has more often seen muted or negative next-day moves, indicating occasional divergence between news tone and price reaction.
Over the past few months, BioNTech has focused on strategic expansion and oncology progress, including the CureVac acquisition closing and encouraging Phase 2 data for pumitamig in TNBC. A 2026 strategic update highlighted €17.2 billion in cash and expectations for 15 Phase 3 trials by year-end 2026. Management changes and exchange-offer milestones further shaped its profile. Today’s earnings date announcement fits an established pattern of scheduled financial updates rather than a new strategic shift.
Market Pulse Summary
This announcement sets the timetable for BioNTech’s fourth quarter and full-year 2025 results and corporate update on March 10, 2026, including an earnings call and webcast. It follows a series of strategic and clinical milestones, such as the CureVac acquisition and late-stage oncology focus. Investors may watch for updated revenue trends, cash deployment plans, and oncology pipeline timelines, comparing them to the previously outlined goals and financial position in recent 6‑K filings.
AI-generated analysis. Not financial advice.
MAINZ, Germany, February 24, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the fourth quarter and full year 2025 on Tuesday, March 10, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (1:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link.
Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at www.BioNTech.com. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visit www.BioNTech.com.
CONTACTS
Investor Relations
Douglas Maffei, PhD
Investors@biontech.de
Media Relations
Jasmina Alatovic
Media@biontech.de
FAQ
When will BioNTech (BNTX) release its Q4 and full-year 2025 results?
How can investors access the BioNTech (BNTX) March 10, 2026 earnings call?
What time is the BioNTech (BNTX) conference call on March 10, 2026?
Will BioNTech (BNTX) provide a replay of the March 10, 2026 webcast?
Do I need to register to join BioNTech's (BNTX) March 10, 2026 earnings call by phone?
